Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAMETA China cohort of savolitinib + durvalumab in MET-driven advanced papillary renal cell carcinoma
CTR20222437Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- May 2023
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of savolitinib, durvalumab, sunitinib in papillary renal cell carcinoma (PRCC), sponsored by AstraZeneca. Started May 2023; status: completed.
02
Drugs
savolitinibdurvalumabsunitinib
03
Conditions
papillary renal cell carcinoma (PRCC)
Beyond the preview
Go deeper on CTR20222437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222437.